Translational Science Group is a preclinical-stage biopharmaceutical company on a mission to eliminate viral infectious disease. Translational Science Group has designed a novel class of broad-spectrum antiviral drugs that are adaptable, scalable, and therapeutically effective against a wide range of emerging and re-emerging viruses. By utilizing disruptive approaches across engineering and medicine, we have developed a proven platform for developing drug candidates with potent antiviral activity against diverse classes of viruses. Whereas conventional approaches are based on a narrow “one bug, one drug” concept, our strategy is driven by a “one drug, many bugs” vision that will lead to clinical solutions for a wide range of viral infections and improve billions of lives around the world. TSG stands for “Translational Science Group”. TSG Therapeutics was formed as a spin-off from Dr. Nam-Joon Cho’s Engineering in Translational Science Group, which is based at Nanyang Technological University in Singapore. We were founded upon a vision to help those who are in need. By translating antiviral research breakthroughs into urgently needed medicines, we aim to realize our vision, today.